<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549935</url>
  </required_header>
  <id_info>
    <org_study_id>The PRIME Study</org_study_id>
    <nct_id>NCT04549935</nct_id>
  </id_info>
  <brief_title>The PRIME Study: A Randomized, Controlled, Prospective Study</brief_title>
  <official_title>A Randomized, Controlled, PRospective Study of the Effectiveness and Safety of the Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg for the treatMEnt of Post-operative Inflammation in Patients Who Plan to Undergo Refractive Lens Exchange (RLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vance Thompson Vision - MT</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vance Thompson Vision - MT</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the outcomes of patients undergoing bilateral RLE surgery with treatment of&#xD;
      dexamethasone intracanilicular insert compared to topical standard care steroid. Desiged to&#xD;
      look at patient preference comparing the insert to drops and will also look at patient&#xD;
      outcomes including inflammatin and risk of cystoid macular edema post-operatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Controlled, Prospective Study design in which one eye (Group A) receives&#xD;
      Dextenza and the second eye (Group B) receives prednisolone acetate 1% QID 1 week, TID 1&#xD;
      week, BID 1 week, and QD 1week, following bilateral RLE surgery. All eyes will receive&#xD;
      topical moxifloxacin QID for one week and topical Ilevro QD for 4 weeks. Moxifloxacin and&#xD;
      Ilevero are used in post-op regardless of the research. Post-operative evaluations to be&#xD;
      performed on Day 1, Day 7, and 1 Month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2020</start_date>
  <completion_date type="Anticipated">August 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Preference</measure>
    <time_frame>Through Month 1</time_frame>
    <description>As measured by adapted COMTOL (Comparison of Ophthalmic Medications for Tolerability) survey (This is measured on a scale of 1-10 with 10 being a worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of eyes that have CME (Cystoid macular edema) post-operatively</measure>
    <time_frame>Through Month 1</time_frame>
    <description>Measured by OCT (Optical Coherence Tomography )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain score per eye (Group A vs Group B)</measure>
    <time_frame>Through Month 1</time_frame>
    <description>Measured by Visual Analog Scale (0-10, 10 being the worst outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative corneal haze</measure>
    <time_frame>Through Month 1</time_frame>
    <description>measured by OCT (Optical Coherence Tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of post-operative corneal haze</measure>
    <time_frame>Through Month 1</time_frame>
    <description>measured by OCT (Optical Coherence Tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior chamber cell count</measure>
    <time_frame>Through Month 1</time_frame>
    <description>measured by SUN Working Group Grading Scheme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity</measure>
    <time_frame>Through Month 1</time_frame>
    <description>measured by ETDRS chart a 4m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Through Month 1</time_frame>
    <description>measured by ETDRS chart a 4m</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Patient Preference</condition>
  <condition>Patient Outcomes</condition>
  <condition>Post-Operative Inflammation</condition>
  <condition>Grade of Post-Operative Cystoid Macular Edema</condition>
  <condition>Rate of Post-Operative Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Group A Dextenza</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Dextenza 0.4mg Opthalmic Insert The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion, The attributes of the insert reduce risks for improper corticosteriod tapering and unwanted peaks and troughs in drug concentration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Topical Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Topical Prednisolone Standard of care topical drop treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza</intervention_name>
    <description>Dextenza 0.4mg</description>
    <arm_group_label>Group A Dextenza</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Prednisolone</intervention_name>
    <description>Standard of care topical drop treatment</description>
    <arm_group_label>Group B Topical Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any adult patient who is planned to undergo bilateral RLE surgery with BCVA 20/30 or&#xD;
             better&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 22 or above the age of 75&#xD;
&#xD;
          -  Patients who are pregnant (must be ruled out in a women of child-bearing age with&#xD;
             pregnancy test).&#xD;
&#xD;
          -  Patients with active infectious ocular or extraocular disease.&#xD;
&#xD;
          -  Patients actively treated with local or systemic immunosuppression including systemic&#xD;
             corticosteriods&#xD;
&#xD;
          -  Paitents with know hypersensitivity to Dexamethasone&#xD;
&#xD;
          -  Patients with severe disease that warrants critical attentino, deemed unsafe for the&#xD;
             study by the investigator&#xD;
&#xD;
          -  Patients with a history of ocular inflammation or macular edema&#xD;
&#xD;
          -  Patients with allergy or inability to receive intracameral antibiotic&#xD;
&#xD;
          -  Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) grater than 1,200&#xD;
             mg/day&#xD;
&#xD;
          -  Patient with a corticosteriod implant (i.e. Ozurdex).&#xD;
&#xD;
          -  Patient with corneal pathology which pre-disposes them to unsatisfactory outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Briana Parker</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Parker</last_name>
      <phone>406-599-5961</phone>
      <email>briana.parker@vancethompsonvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Keeley Puls</last_name>
      <phone>605 371-7075</phone>
      <email>kpuls@vancethompsonvision.com</email>
    </contact_backup>
    <investigator>
      <last_name>Russell Swan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Travis Whitt, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seirra Steiner, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

